Literature DB >> 33212064

Patisiran in hereditary transthyretin-mediated amyloidosis.

Marco Luigetti1, Serenella Servidei2.   

Abstract

Entities:  

Year:  2020        PMID: 33212064     DOI: 10.1016/S1474-4422(20)30397-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  2 in total

1.  Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy.

Authors:  Luca Gentile; Massimo Russo; Marco Luigetti; Giulia Bisogni; Andrea Di Paolantonio; Angela Romano; Valeria Guglielmino; Ilenia Arimatea; Mario Sabatelli; Antonio Toscano; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-19

Review 2.  Novel vectors and approaches for gene therapy in liver diseases.

Authors:  Sheila Maestro; Nicholas D Weber; Nerea Zabaleta; Rafael Aldabe; Gloria Gonzalez-Aseguinolaza
Journal:  JHEP Rep       Date:  2021-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.